BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on developing novel antibacterials for life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed to overcome resistance, block virulence and affect the pathogenesis of harmful bacteria. This enables BioVersys to address the unmet medical need for new treatments against life-threatening bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The company’s most advanced programs address nosocomial infections of A. baumannii (BV100, Phase 2), and tuberculosis (alpibectir, Phase 2a, in collaboration with GSK and the University of Lille, France)
02.09.2025
Regulatory milestones and clinical progress for Swiss biotechs (startupticker.ch)
08.07.2025
From Lab Bench to Bell Ring – Marc Gitzinger on BioVersys' road to IPO (venturelab.swiss)
02.07.2025
BioVersys enters into research and license option agreement with Shionogi & Co (startupticker.ch)
19.03.2025
Biotech updates: A first dosing and a setback (startupticker.ch)
07.02.2025
BioVersys Opens IPO Season at SIX Swiss Exchange (startupticker.ch)
20.09.2016
BioVersys wins the international Innovation Prize by Universal Biotech in Paris
No Jobs
Swiss Technology Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
The Venture Leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
CTI Start-up enables entrepreneurs to realize their innovative idea professionally.
In a process of three phases, over forty experienced coaches guide start-up companies on their way to enter the market successfully and attract financing. At the end of the coaching process, the most promising start-up companies have the opportunity to receive the prestigious CTI Start-up ’Label’. In addition, the companies benefit from the wide CTI Start-up network of industry experts, experienced entrepreneurs, business angels, venture capitalists and has access to foundations such as de Vigier, STI, FIT, Gebert, Rüf, etc.
Until today, CTI Start-up reviewed more than 1 800 projects, and awarded over 200 start-up enterprises with the CTI Start-up Label. Over 85% of these companies are still in business and some have shown remarkable growth, which is a sign that CTI Start-up guides them to sustainable success.
CTI also promotes the culture of entrepreneurship at universities, teaching hospitals, technical institutes as well as universities of applied sciences. CTI Entrepreneurship offers workshops to students on how to bring innovation to the market.
Website:
www.bioversys.com
Headquarter:
Basel
Foundation Date:
September 2008
Technology:
Sectors: